Hims & Hers Health Earnings & Forecasts

Hims & Hers Health (HIMS) earnings history, EPS estimates, revenue forecasts and company guidance.

Earnings Per Share (Non-GAAP)

四半期利益の驚きの金額

会計四半期	報告日	実質EPS	推定EPS	驚き％
Q2	Aug 10, 2026	$-0.37	$-0.05	-640.0 %
Q1	May 11, 2026	$-0.40	$0.04	-1100.0 %
Q4	Feb 23, 2026	$0.08	$0.03	166.7 %
Q3	Nov 3, 2025	$0.09	$0.10	-10.0 %

Quarterly Revenue (Billions)

四半期売上高の驚きの金額

会計四半期	報告日	実際の収益	推定収益	驚き％
Q2	Aug 10, 2026	$753.21M	$722.14M	4.30 %
Q1	May 11, 2026	$608.10M	$617.41M	-1.51 %
Q4	Feb 23, 2026	$617.82M	$618.03M	-0.03 %
Q3	Nov 3, 2025	$598.98M	$581.38M	3.03 %

Hims & Hers Health Guidance

Hims & Hers Health (HIMS) は、8 10, 2026日にQ3の2026に関するガイダンスを直近で発表しました。同社は当期の売上高を$880M - $900Mの範囲と予想しています。

以前のガイダンスと比較して、Hims & Hers Healthは売上高予測を以前の範囲である引き下げから$3.1B - $3.3Bに引き上げました。

Hims & Hers Healthは、32から11 7, 2022の間に8 10, 2026ガイダンスの更新を発表しました。During this period, the company raised its outlook 13 times and lowered it 15 times, providing investors with insight into management's evolving expectations.

Recent Earnings Results

Metric	Q2 '26	Q1 '26	Q4 '25	Q3 '25
Earnings Per Share (Non-GAAP)
Estimate	$-0.05	$0.04	$0.03	$0.10
Actual	$-0.37	$-0.40	$0.08	$0.09
Surprise	-640.0%	-1100.0%	+166.7%	-10.0%
Revenue
Estimate	$722.1M	$617.4M	$618.0M	$581.4M
Actual	$753.2M	$608.1M	$617.8M	$599.0M
Surprise	+4.30%	-1.51%	-0.03%	+3.03%

Analyst Estimates — Forward PeriodsSource: Wall Street consensus

Metric	Q3 '26E	Q4 '26E	Q1 '27E	Q2 '27E
Earnings Per Share (Non-GAAP)
Consensus	$0.08	$0.15	$-0.03	$0.06
Revenue
Consensus	$894.4M	$951.7M	—	—

More with Benzinga EdgeGet Access

Earnings & Guidance News

Hims & Hers Health: Investments Necessary For Long-Term Incremental Growth, Says Bullish Analyst

HIMS stock edges lower after mixed Q2 results. Needham analyst maintains Buy rating, raises PT to $42. Company's revenue up 38.2% YoY.

Priya Nigam

Hims & Hers Shares Drop After Mixed Q2 Earnings — Details

Hims & Hers posted Q2 results - here are the details you need to know.

Erica Kollmann

PRO
Hims & Hers Health Sees Q3 Sales $880.000M-$900.000M vs $793.071M Est

Hims & Hers Health (NYSE:HIMS) sees Q3 sales of $880.000 million-$900.000 million vs $793.071 million analyst estimate.

Benzinga Newsdesk

PRO
Hims & Hers Health Raises FY2026 Sales Guidance from $2.800B-$3.000B to $3.100B-$3.300B vs $2.928B Est

Hims & Hers Health (NYSE:HIMS) raises FY2026 sales outlook from $2.800 billion-$3.000 billion to $3.100 billion-$3.300 billion vs $2.928 billion estimate.

Benzinga Newsdesk

PRO
Hims & Hers Health Q2 EPS $(0.37) Misses $(0.03) Estimate, Sales $753.214M Beat $699.889M Estimate

Hims & Hers Health (NYSE:HIMS) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.03) by 1133.33 percent. This is a 317.65 percent decrease over earnings of $0.17 per

Benzinga Newsdesk

Hims & Hers Health Likely To Report Q2 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

HIMS to release Q2 earnings on Aug. 10, expected to report a loss of 5 cents/share. FDA panel voted to add BPC-157 to compounding list. Stock rose 6.5% on Friday.

Avi Kapoor

Hims & Hers Health Inc